Publications
Found 2 results
Filters: Author is H. Montoya-Fuentes [Clear All Filters]
“Association of TP53 gene codon 72 polymorphism with endometriosis in Mexican women”, vol. 11, pp. 1401-1408, 2012.
,
Akahane T, Sekizawa A, Purwosunu Y, Nagatsuka M, et al. (2007). The role of p53 mutation in the carcinomas arising from endometriosis. Int. J. Gynecol. Pathol. 26: 345-351.
http://dx.doi.org/10.1097/pgp.0b013e31802b41a8
PMid:17581423
Ammendola M, Gloria-Bottini F, Sesti F, Piccione E, et al. (2008). Association of p53 codon 72 polymorphism with endometriosis. Fertil. Steril. 90: 406-408.
http://dx.doi.org/10.1016/j.fertnstert.2007.06.051
PMid:17931634
Ayala YR and Mota GM (2007). Endometriosis: physiopathology and investigation trends (first part). Ginecol. Obstet. Mex. 75: 477-483.
Chang CC, Hsieh YY, Tsai FJ, Tsai CH, et al. (2002). The proline form of p53 codon 72 polymorphism is associated with endometriosis. Fertil. Steril. 77: 43-45.
http://dx.doi.org/10.1016/S0015-0282(01)02938-7
Chiurillo MA, Moran Y, Cañas M and Valero G (2010). Distribución del polimorfismo codon 72 de TP53 en Venezuela: implicaciones étnicas y Geográficas. Interciencia 35: 202-206.
Doosti A, Zamani M, Ghasemi P, Taherin S, et al. (2011). Association of the p53 codon 72 polymorphism with colorectal cancer in South West of Iran. Sci. Res. Essays 6: 3148-3152.
Dunselman G (2002). Endometriosis. Patogenia de los Implantes Endometriósicos. In: Reproducción Humana (Pellicer A and Simón C, eds.). Mc GrawHill, España, 191-197.
Felix A, Nogales FF and Arias-Stella J (2010). Polypoid endometriosis of the uterine cervix with Arias-Stella reaction in a patient taking phytoestrogens. Int. J. Gynecol. Pathol. 29: 185-188.
http://dx.doi.org/10.1097/PGP.0b013e3181b7015e
PMid:20173505
Ghasemi N, Karimi-Zarchi M, Mortazavi-Zadeh MR and Atash-Afza A (2010). Evaluation of the frequency of TP53 gene codon 72 polymorphisms in Iranian patients with endometrial cancer. Cancer Genet. Cytogenet. 196: 167-170.
http://dx.doi.org/10.1016/j.cancergencyto.2009.09.013
PMid:20082853
Giudice LC and Kao LC (2004). Endometriosis. Lancet 364: 1789-1799.
http://dx.doi.org/10.1016/S0140-6736(04)17403-5
Goodman C, Jeyendran RS and Coulam CB (2009). P53 tumor suppressor factor, plasminogen activator inhibitor, and vascular endothelial growth factor gene polymorphisms and recurrent implantation failure. Fertil. Steril. 92: 494-498.
http://dx.doi.org/10.1016/j.fertnstert.2008.07.022
PMid:18829023
Gruppo Italiano per lo Studio dell'Endometriosi (2001). Relationship between stage, site and morphological characteristics of pelvic endometriosis and pain. Hum. Reprod. 16: 2668-2671.
Gylfason JT, Kristjansson KA, Sverrisdottir G, Jonsdottir K, et al. (2010). Pelvic endometriosis diagnosed in an entire nation over 20 years. Am. J. Epidemiol. 172: 237-243.
http://dx.doi.org/10.1093/aje/kwq143
PMid:20616202
Hsieh YY and Lin CS (2006). P53 codon 11, 72, and 248 gene polymorphisms in endometriosis. Int. J. Biol. Sci. 2: 188- 193.
http://dx.doi.org/10.7150/ijbs.2.188
PMid:16896365 PMCid:1525214
Kang HJ, Feng Z, Sun Y, Atwal G, et al. (2009). Single-nucleotide polymorphisms in the p53 pathway regulate fertility in humans. Proc. Natl. Acad. Sci. U. S. A. 106: 9761-9766.
http://dx.doi.org/10.1073/pnas.0904280106
PMid:19470478 PMCid:2700980
Kern SE, Kinzler KW, Bruskin A, Jarosz D, et al. (1991). Identification of p53 as a sequence-specific DNA-binding protein. Science 252: 1708-1711.
http://dx.doi.org/10.1126/science.2047879
PMid:2047879
Kobayashi H, Kajiwara H, Kanayama S, Yamada Y, et al. (2009). Molecular pathogenesis of endometriosis-associated clear cell carcinoma of the ovary (review). Oncol. Rep. 22: 233-240.
PMid:19578761
Liu G, Miller DP, Zhou W, Thurston SW, et al. (2001). Differential association of the codon 72 p53 and GSTM1 polymorphisms on histological subtype of non-small cell lung carcinoma. Cancer Res. 61: 8718-8722.
PMid:11751390
Mandai M, Yamaguchi K, Matsumura N, Baba T, et al. (2009). Ovarian cancer in endometriosis: molecular biology, pathology, and clinical management. Int. J. Clin. Oncol. 14: 383-391.
http://dx.doi.org/10.1007/s10147-009-0935-y
PMid:19856044
Miller SA, Dykes DD and Polesky HF (1988). A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 16: 1215.
http://dx.doi.org/10.1093/nar/16.3.1215
PMid:3344216 PMCid:334765
Nouri K, Ott J, Krupitz B, Huber JC, et al. (2010). Family incidence of endometriosis in first-, second-, and third-degree relatives: case-control study. Reprod. Biol. Endocrinol. 8: 85.
http://dx.doi.org/10.1186/1477-7827-8-85
PMid:20618992 PMCid:2911462
Peppone LJ, Piazza KM, Mahoney MC, Morrow GR, et al. (2009). Associations between adult and childhood smoke exposures and fecundity and fetal loss among women who visited a cancer hospital. Tob. Control 18: 115-120.
http://dx.doi.org/10.1136/tc.2008.027961
PMid:19039010 PMCid:2886518
Ribeiro Junior CL, Arruda JT, Silva CT and Moura KK (2009). Analysis of p53 codon 72 gene polymorphism in Brazilian patients with endometriosis. Genet. Mol. Res. 8: 494-499.
http://dx.doi.org/10.4238/vol8-2gmr593
PMid:19551637
Sanguinetti CJ, Dias NE and Simpson AJ (1994). Rapid silver staining and recovery of PCR products separated on polyacrylamide gels. Biotechniques 17: 914-921.
PMid:7840973
Shiverick KT and Salafia C (1999). Cigarette smoking and pregnancy I: ovarian, uterine and placental effects. Placenta 20: 265-272.
http://dx.doi.org/10.1053/plac.1998.0377
PMid:10329346
Själander A, Birgander R, Saha N, Beckman L, et al. (1996). p53 polymorphisms and haplotypes show distinct differences between major ethnic groups. Hum. Hered. 46: 41-48.
http://dx.doi.org/10.1159/000154324
PMid:8825462
Suárez-Rincon AE, Moran-Moguel MC, Montoya-Fuentes H, Gallegos-Arreola MP, et al. (2002). Polymorphism in codon 72 of the p53 gene and cervico-uterine cancer risk in Mexico. Ginecol. Obstet. Mex. 70: 344-348.
PMid:12221910
Sunderam S, Chang J, Flowers L, Kulkarni A, et al. (2009). Assisted reproductive technology surveillance-United States, 2006. MMWR Surveill Summ. 58: 1-25.
PMid:19521336
Thomas M, Kalita A, Labrecque S, Pim D, et al. (1999). Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol. Cell Biol. 19: 1092-1100.
PMid:9891044 PMCid:116039
Troyer MR (2007). Differential diagnosis of endometriosis in a young adult woman with nonspecific low back pain. Phys. Ther. 87: 801-810.
http://dx.doi.org/10.2522/ptj.20060141
PMid:17442838
“Human papillomavirus viral load in cervical intraepithelial neoplasia as a prognostic factor in a Mexican population”, vol. 11, pp. 4720-4727, 2012.
, Andersson S, Safari H, Mints M, Lewensohn-Fuchs I, et al. (2005). Type distribution, viral load and integration status of high-risk human papillomaviruses in pre-stages of cervical cancer (CIN). Br. J. Cancer 92: 2195-2200.
http://dx.doi.org/10.1038/sj.bjc.6602648
PMid:15942630 PMCid:2361820
Boulet GA, Benoy IH, Depuydt CE, Horvath CA, et al. (2009). Human papillomavirus 16 load and E2/E6 ratio in HPV16- positive women: biomarkers for cervical intraepithelial neoplasia ≥2 in a liquid-based cytology setting? Cancer Epidemiol. Biomarkers Prev. 18: 2992-2999.
http://dx.doi.org/10.1158/1055-9965.EPI-09-0025
PMid:19861526
Briolat J, Dalstein V, Saunier M, Joseph K, et al. (2007). HPV prevalence, viral load and physical state of HPV-16 in cervical smears of patients with different grades of CIN. Int. J. Cancer 121: 2198-2204.
http://dx.doi.org/10.1002/ijc.22959
PMid:17657742
Cain JM and Howett MK (2000). Preventing cervical cancer. Science 288: 1753-1755.
http://dx.doi.org/10.1126/science.288.5472.1753
PMid:10877694
Castle PE, Schiffman M and Wheeler CM (2004). Hybrid capture 2 viral load and the 2-year cumulative risk of cervical intraepithelial neoplasia grade 3 or cancer. Am. J. Obstet. Gynecol. 191: 1590-1597.
http://dx.doi.org/10.1016/j.ajog.2004.05.018
PMid:15547529
Castle PE, Schiffman M, Scott DR, Sherman ME, et al. (2005). Semiquantitative human papillomavirus type 16 viral load and the prospective risk of cervical precancer and cancer. Cancer Epidemiol. Biomarkers Prev. 14: 1311-1314.
http://dx.doi.org/10.1158/1055-9965.EPI-04-0799
PMid:15894692
Castle PE, Solomon D, Wheeler CM, Gravitt PE, et al. (2008). Human papillomavirus genotype specificity of hybrid capture 2. J. Clin. Microbiol. 46: 2595-2604.
http://dx.doi.org/10.1128/JCM.00824-08
PMid:18579716 PMCid:2519476
Clavel C, Masure M, Bory JP, Putaud I, et al. (2001). Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br. J. Cancer 84: 1616-1623.
http://dx.doi.org/10.1054/bjoc.2001.1845
PMid:11401314 PMCid:2363679
Einstein MH (2008). Acquired immune response to oncogenic human papillomavirus associated with prophylactic cervical cancer vaccines. Cancer Immunol. Immunother. 57: 443-451.
http://dx.doi.org/10.1007/s00262-007-0440-y
PMid:18157723
Fiander AN, Hart KW, Hibbitts SJ, Rieck GC, et al. (2007). Variation in human papillomavirus type-16 viral load within different histological grades of cervical neoplasia. J. Med. Virol. 79: 1366-1369.
http://dx.doi.org/10.1002/jmv.20875
PMid:17607770
Grce M, Matovina M, Milutin-Gasperov N and Sabol I (2010). Advances in cervical cancer control and future perspectives. Coll. Antropol. 34: 731-736.
PMid:20698164
Hesselink AT, Berkhof J, Heideman DA, Bulkmans NW, et al. (2009). High-risk human papillomavirus DNA load in a population-based cervical screening cohort in relation to the detection of high-grade cervical intraepithelial neoplasia and cervical cancer. Int. J. Cancer 124: 381-386.
http://dx.doi.org/10.1002/ijc.23940
PMid:19003961
Ho GY, Burk RD, Klein S, Kadish AS, et al. (1995). Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J. Natl. Cancer Inst. 87: 1365-1371.
http://dx.doi.org/10.1093/jnci/87.18.1365
PMid:7658497
Javier RT and Butel JS (2008). The history of tumor virology. Cancer Res. 68: 7693-7706.
http://dx.doi.org/10.1158/0008-5472.CAN-08-3301
PMid:18829521 PMCid:3501656
Josefsson AM, Magnusson PK, Ylitalo N, Sorensen P, et al. (2000). Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: a nested case-control study. Lancet 355: 2189-2193.
http://dx.doi.org/10.1016/S0140-6736(00)02401-6
Lillo FB and Uberti-Foppa C (2006). Human papillomavirus viral load: a possible marker for cervical disease in HIV-infected women. J. Antimicrob. Chemother. 57: 810-814.
http://dx.doi.org/10.1093/jac/dkl073
PMid:16556637
Lorincz AT, Castle PE, Sherman ME, Scott DR, et al. (2002). Viral load of human papillomavirus and risk of CIN3 or cervical cancer. Lancet 360: 228-229.
http://dx.doi.org/10.1016/S0140-6736(02)09463-1
McMurray HR, Nguyen D, Westbrook TF and McAnce DJ (2001). Biology of human papillomaviruses. Int. J. Exp. Pathol. 82: 15-33.
http://dx.doi.org/10.1046/j.1365-2613.2001.00177.x
PMid:11422538 PMCid:2517699
Mendizabal-Ruiz AP, Morales JA, Ramirez-Jirano LJ, Padilla-Rosas M, et al. (2009). Low frequency of human papillomavirus DNA in breast cancer tissue. Breast Cancer Res. Treat. 114: 189-194.
http://dx.doi.org/10.1007/s10549-008-9989-1
PMid:18373273
Moberg M, Gustavsson I, Wilander E and Gyllensten U (2005). High viral loads of human papillomavirus predict risk of invasive cervical carcinoma. Br. J. Cancer 92: 891-894.
http://dx.doi.org/10.1038/sj.bjc.6602436
PMid:15756259 PMCid:2361906
Nobbenhuis MA, Walboomers JM, Helmerhorst TJ, Rozendaal L, et al. (1999). Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet 354: 20-25.
http://dx.doi.org/10.1016/S0140-6736(98)12490-X
Nobbenhuis MA, Helmerhorst TJ, van den Brule AJ, Rozendaal L, et al. (2001). Cytological regression and clearance of high-risk human papillomavirus in women with an abnormal cervical smear. Lancet 358: 1782-1783.
http://dx.doi.org/10.1016/S0140-6736(01)06809-X
Remmink AJ, Walboomers JM, Helmerhorst TJ, Voorhorst FJ, et al. (1995). The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: natural history up to 36 months. Int. J. Cancer 61: 306-311.
http://dx.doi.org/10.1002/ijc.2910610305
PMid:7729939
Sargent A, Bailey A, Turner A, Almonte M, et al. (2010). Optimal threshold for a positive hybrid capture 2 test for detection of human papillomavirus: data from the ARTISTIC trial. J. Clin. Microbiol. 48: 554-558.
http://dx.doi.org/10.1128/JCM.00896-09
PMid:20007387 PMCid:2815647
Schlecht NF, Trevisan A, Duarte-Franco E, Rohan TE, et al. (2003). Viral load as a predictor of the risk of cervical intraepithelial neoplasia. Int. J. Cancer 103: 519-524.
http://dx.doi.org/10.1002/ijc.10846
PMid:12478669
Seaman WT, Andrews E, Couch M, Kojic EM, et al. (2010). Detection and quantitation of HPV in genital and oral tissues and fluids by real time PCR. Virol. J. 7: 194.
http://dx.doi.org/10.1186/1743-422X-7-194
PMid:20723234 PMCid:2933591
Sun CA, Lai HC, Chang CC, Neih S, et al. (2001). The significance of human papillomavirus viral load in prediction of histologic severity and size of squamous intraepithelial lesions of uterine cervix. Gynecol. Oncol. 83: 95-99.
http://dx.doi.org/10.1006/gyno.2001.6336
PMid:11585419
Sun CA, Liu JF, Wu DM, Nieh S, et al. (2002). Viral load of high-risk human papillomavirus in cervical squamous intraepithelial lesions. Int. J. Gynaecol. Obstet. 76: 41-47.
http://dx.doi.org/10.1016/S0020-7292(01)00529-X
Wensveen CW, Kagie MJ, Nagelkerke NJ, Veldhuizen RW, et al. (2005). Can viral load, semi-quantitatively evaluated, of human papillomavirus predict cytological or histological outcome in women with atypical squamous or glandular cells of undetermined significance cytology? Eur. J. Gynaecol. Oncol. 26: 393-397.
PMid:16122186
Winer RL, Lee SK, Hughes JP, Adam DE, et al. (2003). Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am. J. Epidemiol. 157: 218-226.
http://dx.doi.org/10.1093/aje/kwf180
PMid:12543621
Xi LF, Kiviat NB, Galloway DA, Zhou XH, et al. (2008). Effect of cervical cytologic status on the association between human papillomavirus type 16 DNA load and the risk of cervical intraepithelial neoplasia grade 3. J. Infect. Dis. 198: 324-331.
http://dx.doi.org/10.1086/589715
PMid:18627250 PMCid:2784608
Xu Y, Dotto J, Hui Y, Lawton K, et al. (2009). High grade cervical intraepithelial neoplasia and viral load of high-risk human papillomavirus: significant correlations in patients of 22 years old or younger. Int. J. Clin. Exp. Pathol. 2: 169-175.
PMid:19079652 PMCid:2583634
Ylitalo N, Sorensen P, Josefsson AM, Magnusson PK, et al. (2000). Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: a nested case-control study. Lancet 355: 2194-2198.
http://dx.doi.org/10.1016/S0140-6736(00)02402-8
Zielinski GD, Snijders PJ, Rozendaal L, Voorhorst FJ, et al. (2001). HPV presence precedes abnormal cytology in women developing cervical cancer and signals false negative smears. Br. J. Cancer 85: 398-404.
http://dx.doi.org/10.1054/bjoc.2001.1926
PMid:11487272 PMCid:2364067